JPMorgan Healthcare Leaders ETF (JDOC) has seen unusual trading volume, which is 24× higher than its average daily volume.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Among JDOC’s largest positions, Eli Lilly And Company is in focus after the drugmaker reported completion of a Phase 1 pediatric study for its experimental diabetes drug LY3209590 and drew fresh bullish commentary from Barclays, which reiterated a Buy rating and a $1,350 price target while calling the stock its top pharma pick ahead of an April 10 FDA decision on the weight-loss pill Orforglipron. Medtronic, another notable holding, also made headlines as Bank of America Securities maintained a Buy rating with a $110 price target, while the broader analyst consensus on the stock remains a Moderate Buy with meaningful upside from current levels.